Previous 10 | Next 10 |
BEDFORD, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate in two upcoming investor conferences. Citi’s 14 th Annual Biotech Conference Four Seasons Hotel, Bos...
Homology Medicines (NASDAQ: FIXX ): Q2 GAAP EPS of -$0.61 misses by $0.06 . More news on: Homology Medicines, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- Phase 1/2 pheNIX Study of HMI-102 Gene Therapy Candidate for Adults with PKU Continues, Additional Sites Enrolling and Initial Data Expected by Year End - - Fast Track Designation Granted in the U.S. for HMI-102, A...
BEDFORD, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate in a fireside chat at the Canaccord Genuity 39th Annual Growth Conference on Wednesday, August 7, at 11:30 a.m. ET...
Homology Medicines ( FIXX -20% ) slumps on a 6x surge in volume in apparent response to an abstract published on July 21 by bioRxiv (pronounced "bio-archive"). More news on: Homology Medicines, Inc., Healthcare stocks news, Stocks on the move, Read more ...
- Celgene Executive with Early- and Late-Stage Global Clinical Development Experience Joins as Homology Advances Lead Gene Therapy Program for PKU Through the Clinic - BEDFORD, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines compan...
- Sam Rasty, Ph.D., Departs as Chief Operating Officer to Lead an Emerging Biotech - BEDFORD, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today changes to its leadership team, which positions the Company for...
- Phase 1/2 pheNIX Study of Gene Therapy Candidate HMI-102 is Underway and Initial Clinical Data is Anticipated by Year End - BEDFORD, Mass., June 17, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of dat...
BEDFORD, Mass., June 13, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will present at the JMP Securities Life Sciences Conference on Wednesday, June 19, at 8:30 a.m. ET at The ...
- Enrollment in the pheNIX Study Marks First Gene Therapy Clinical Trial for PKU - BEDFORD, Mass., June 10, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has commenced enrollment of the Phase 1/2 pheNIX trial for...
News, Short Squeeze, Breakout and More Instantly...
Homology Medicines Inc. Company Name:
FIXX Stock Symbol:
NASDAQ Market:
Homology Medicines Inc. Website:
2024-03-25 09:02:02 ET Homology Medicines Inc (FIXX) announced stock split at a ratio of 1-for-18 on 2024-03-25 ... Full story available on KlickAnalytics.com
BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstandi...
Homology Medicines has an initial 180-day period through June 26, 2024 to regain compliance with Minimum Bid Price Requirement BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it received notification (“ Nasdaq Notif...